Safety and Efficacy Study of Small Interfering RNA Molecule (Cand5) to Treat Diabetic Macular Edema

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2006
The purpose of this study is to evaluate the pharmacokinetics, safety and preliminary efficacy of 3 doses of Cand5. Cand5 is a small interfering RNA molecule that selectively silences the mRNA encoding for VEGF. The target population are patients with diabetic macular edema.
Epistemonikos ID: 4e53d5a8b82f2170423308e8d3ff7981f7e151cc
First added on: May 04, 2024